A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment

PHASE4CompletedINTERVENTIONAL
Enrollment

511

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Kidney DiseasesCoronary Artery Disease
Interventions
DRUG

Regadenoson

IV

DRUG

Placebo

IV

Trial Locations (41)

10010

New York

11413

Springfield Gardens

15701

Indiana

16635

Duncansville

16686

Tyrone

19610

Wyomissing

19713

Newark

19808

Wilmington

29303

Spartanburg

29425

Charleston

32789

Winter Park

32809

Orlando

33173

Miami

33308

Fort Lauderdale

34655

Trinity

36207

Anniston

37920

Knoxville

38540

Ellijay

45505

Springfield

48202

Detroit

48504

Flint

55415

Minneapolis

60616

Chicago

72204

Little Rock

73103

Oklahoma City

77055

Houston

77074

Houston

77478

Sugar Grove

90017

Los Angeles

90022

Los Angeles

90202

Bell Gardens

92691

Mission Viejo

92704

Santa Ana

92835

Fullerton

92845

Garden Grove

94609

Oakland

95661

Roseville

97701

Bend

04210

Auburn

07450

Ridgewood

08873

Somerset

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY